Gemcitabine and Vinorelbine (GemVin) Regimen-Reference-Cited by-同舟云学术

Gemcitabine and Vinorelbine (GemVin) Regimen

Published:2014-06 Issue:6 Volume:49 Page:508-516
ISSN:0018-5787
Container-title:Hospital Pharmacy
language:en
Short-container-title:Hosp Pharm

Author:

Shang Elizabeth Y.¹,Solimando Dominic A.²,Waddell J. Aubrey³

Affiliation:

1. American Red Cross, Department of Pharmacy, Walter Reed National Military Medical Center, Bethesda, Maryland.

2. Oncology Pharmacy Services, Inc., 4201 Wilson Blvd #110–545, Arlington, VA 22203

3. University of Tennessee College of Pharmacy, Pharmacy Department, Blount Memorial Hospital, 907 E. Lamar Alexander Parkway, Maryville, TN 37804

Abstract

The complexity of cancer chemotherapy requires pharmacists be familiar with the complicated regimens and highly toxic agents used. This column reviews various issues related to preparation, dispensing, and administration of antineoplastic therapy, and the agents, both commercially available and investigational, used to treat malignant diseases.

Publisher

SAGE Publications

Subject

Pharmacology (medical),Pharmacology,Pharmacy

Link

http://journals.sagepub.com/doi/pdf/10.1310/hpj4906-508

Reference58 articles.

1. Phase I-II Trial of Gemcitabine-Based First-Line Chemotherapies for Small Cell Lung Cancer in Elderly Patients with Performance Status 0-2: The G-Step Trial

2. Combination chemotherapy of gemcitabine and vinorelbine for patients in stage IIIB–IV non-small cell lung cancer: a phase II study of the West Japan Thoracic Oncology Group (WJTOG) 9908

3. Randomized Phase II Study of Carboplatin-Paclitaxel or Gemcitabine-Vinorelbine in Patients With Advanced Nonsmall Cell Lung Cancer and a Performance Status of 2

4. Randomized phase II study of carboplatin/gemcitabine versus vinorelbine/gemcitabine in patients with advanced nonsmall cell lung cancer

5. Activity and toxicity of gemcitabine and gemcitabine+vinorelbine in advanced non-small-cell lung cancer elderly patients

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cost-effectiveness of pembrolizumab versus brentuximab vedotin for patients with relapsed or refractory classical Hodgkin’s lymphoma: a United States payer perspective;Journal of Medical Economics;2018-11-13